IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

A Systematic Review on Transdermal Drug Delivery Patches.

Sakshi kalane, Kunal Pomane, Rushikesh Gawade

Guide- Prof. Bhagyashree Gaikwad

(M pharm. Pharmaceutics)

B Pharmacy Final Year Students, Sarsam College of Pharmacy Palshiwadi.

Dr. Babasaheb Ambedkar Technological University, Lonere, Maharashtra, India.

Abstract:

inventions in transdermal delivery systems (TDS) have made important benefactions to medical practice by furnishing advances in the delivery of treatment with being and new medicines. moment about 74 of medicines are taken orally and are set up not to be as active as asked. To ameliorate similar characters transdermal medicine delivery system was surfaced. medicine delivery through the skin to achieve a systemic etc. of a medicine is generally known as transdermal medicine delivery and differs from traditional topical medicine delivery. Transdermal medicine delivery systems can ameliorate the remedial and safety of the medicines because medicine delivered through the skin at a destined and controlled rate. Skin is the important point of medicine operation for both the original and systemic goods. Transdermal medicine delivery system (TDDS) has several advantages over conventional system; TDDS of errs sustained medicine release, avoidance of first pass effect, patient compliance, ease of operation and junking in case of toxin as well as drop in the side goods as compared with conventional remedy. The stratum corneum acts as a hedge that limits the penetration of substances through the skin and this limitation can be overcome by saturation enhancing ways. The main disadvantage to transdermal delivery systems stems from the fact that the skin is a veritably effected hedge; as a result, only specifics whose motes are small enough to access the skin can be delivered in this system. A wide variety of medicinal are now available in transdermal patch form. Characterization of transdermal patch is use to check its quality, size, time of onset & duration, tenacious property, consistence, weight of patch, humidity of content, uniformity & cutaneous toxicological studies.

Keywords: Transdermal Patches, Transdermal Drug Delivery System, Skin, matrix, delivery system, Polymer matrix.

Introduction:

First transdermal patch approved in 1979 by FDA was Scopolamine for stir sickness. Alternate patch approved in 1981 was Nitroglycerine. currently several patches are available in the request for transdermal use. Some of them are Clonidine, Testosterone, Fentanyl, Nicotine, Hormones etc. these patches are generally applied from 1 to 7 days depending upon colorful conditions. Oral route is most generally used route for medicine delivery, but due to some major failings similar as poor B.A., first pass act and the capability to produce change of medicine position in blood. Topical or Transdermal delivery of anti-analgesic medicines has gained elevation in recent times, owing to its capability to give concentrated and largely localized pain relief directly to a specific area of the body, unlike oral medicine delivery which frequently causes side- goods as it winds its way through the gastrointestinal tract. still, in malignancy of its benefits like targeted and concentrated medicine delivery, the transdermal operation of hydrophobic medicines is significantly limited by the remotest subcaste of mortal skin (stratum corneum). Transdermal delivery not only provides controlled, constant administration of the medicine, but also allows nonstop input of medicines with short natural half- lives and eliminates palpitated entry into systemic rotation, which frequently causes undesirable side goods. therefore, colorful forms of Novel medicine delivery systems similar as Transdermal medicine delivery systems, Controlled release systems, Transmucosal delivery systems etc. Several important advantages of transdermal medicine delivery are limitation of hepatic first pass metabolism, improvement of remedial e activeness and conservation of steady tube position of the medicine. The first Transdermal system, Transdermal- Versifier was approved by FDA in 1979 for the forestallment of nausea and puking associated with trip, particularly by ocean. The substantiation of percutaneous medicine immersion may be set up through measurable blood situations of the medicine, sensible excretion of the medicine and its metabolites in the urine and through the clinical response of the case to the administered medicine remedy.

Physiology Of the Skin

Skin of an average adult body covers a face of roughly 2 m 2 and receives about one- third of the blood circulating through the body. Skin contains an upmost subcaste, epidermis which has morphologically distinct regions; rudimentary subcaste, spiny subcaste, stratum granulosum and upper utmost stratum corneum, it consists of largely cornified(dead) cells bedded in a nonstop matrix of lipid membranous wastes. These extracellular membranes are unique in their compositions and are composed of ceramides, cholesterol and free adipose acids. The mortal skin face is known to contain, on an average, 10- 70 hair follicles and 200- 250 sweat tubes on every square centimeter of the skin area. It's one of the most readily accessible organs of the mortal. Skin Epidermis In a typical part of the epidermis there are a number of different strata in which the cells have distinct anatomical features. From below, the first stratum is the rudimentary subcaste or subcaste of Malpighi. Its cells are substantially polygonal in shape, the deepest tending to a spherical columnar form, and the most superficial getting kindly flattened. Active mitotic proliferation takes place in the deeper layers, the development of new cells leading to a gradational relegation of the aged cells towards the face. Hence, this stratum is also called stratum germinativum. The epidermis is quite avascular, and between the cells of stratum germinativum there are fine intercellular channels which presumably allow the transmission of nutrient fluids deduced from capillary blood vessels in the conterminous dermis. These channels are bridged across by delicate protoplasmic vestments connecting one cell with another. The stratum germinativum, thus, appears to be syncytium of cells.



Fig 1. Physiology structure of skin.

Dermis:

The dermis or corium consists of a thick felt work of connective towel in which packets of collagenous filaments predominate, mingled with a certain proportion of elastic towel in superficial situations. Dermis contains fine conglomerates of blood vessels, lymphatics and jitters, hair follicles, sweat glands and sebaceous glands.31, 32 the thicker the epidermis; thus, the more prominent are the papillae.

Advantages of Transdermal medicine delivery system.

1. Reduces first- pass metabolism effect and GI incompatibility.
2. Sustains remedial medicine situations.
3. Permits tone- administration.
4. Ameliorate tolerance compliance
5. Long amusement medicine delivery.

Disadvantages of Transdermal medicine delivery system.

1. medicines that bear high blood situations cannot be administered.

2. The patches can be uncomfortable to wear.

3. diurnal cure further than 10 mg is not possible

4. Original vexation is a major problem

5. medicines that bear high blood situations are infelicitous.



Table 1: various methods used to enhance the skin penetration.

Types of Transdermal Patches

a. Single- Subcaste- medicine- In- Adhesive

The tenacious subcaste of this system contains the medicine. In this type of patch, the tenacious subcaste not only serves to cleave the colorful layers together, along with the entire system to the skin, but is also responsible for the releasing of the medicine. The tenacious subcaste is girdled by a temporary liner and a backing.

b. Multi- Layer- Drug – In- Adhesive

The multi-layer medicine- in tenacious patch is analogous to the single- subcaste system in that both tenacious layers are also responsible for the releasing of the medicine. One of the layers is for immediate release of the medicine and the other subcaste is for control release of medicine from the force. The multi-layer system is different still in that it adds another subcaste of medicine- in- glue, generally separated by a membrane multi-layer medicine- in- Adhesive (but not in all cases). This patch also has a temporary liner- subcaste and an endless backing

c.Reservoir

Unlike the Single- subcaste and multi-layer medicine- in- glue systems the force transdermal system has a separate medicine subcaste. The medicine subcaste is a liquid cube containing a medicine result or suspense separated by the tenacious subcaste. This patch is also backed by the backing subcaste. In this type of system, the rate of release is zero order.

d. Matrix

The Matrix system has a medicine subcaste of a circumfluous matrix containing a medicine result or suspense. The tenacious subcaste in this patch surrounds the medicine subcaste incompletely overlaying it. Also known as a monolithic device.



Fig 2. Design of drug in adhesive type transdermal patch.



Fig 3. Design of reservoir type transdermal patch.



Fig 4. Design of matrix type transdermal patch.

The factors of Transdermal device include

Polymer matrix

Drug

Saturation enhancers

Other excipients

Polymer Matrix

The polymer controls the release of the medicine from the device. The following criteria should be satisfied for a polymer to be used in transdermal patches.

a) Molecular weight, chemical functionality of the polymer should be similar that the specific medicine di uses duly and gets released through it

. b) The polymer should be stable

. c) The polymer should be nontoxic

d) The polymer should be fluently of manufactured

e) The polymer should be an affordable

f) The polymer and its declination product must be nontoxic or non-antagonistic to the host

g) large quantities of the active agent are incorporated into it.

Table 2: showing different types of polymers.

Natural Polymers	Synthetic Polymers	Synthetic Elastomers
Cellulose derivatives	Poly vinyl alcohol	Hydrin rubber
Gelatin	Poly vinyl chloride	Silicone rubber
Waxes	Polyethylene	Polybutadiene
Proteins	Polypropylene	Nitrile
Gum	Polyamide	Acrylonitrile
Shellac	Polyurea	Neoprene
Natural rubber	Acetal copolymer	Chloroprene
Starch	Polystyrene	Polysiloxane
Chitosan	Epoxy	

Drug:

For successfully developing a Transdermal medicine delivery system, the medicine should be chosen with great care. The following are some of the desirable parcels of a medicine for Transdermal delivery.

Saturation Enhancers:

Saturation enhancers or promoters are agents that have no remedial parcels of their own but can transport the sorption of medicines from medicine delivery systems onto the skin.11 The flux, of medicines across the skin can be written as J = D DC/ dx Where D is the prolixity measure and is a function of size, shape and inflexibility of the di using patch as well as the membrane resistance; C is the attention of the di using species; x is the spatial match. Anionic Surfactants Dioctyl sulfosuccinate, Sodium lauryl sulphate, Decode Dimethyl sulphoxide etc. Nonionic Surfactants Pluronic F127, Pluronic F68, etc. eclectic Chemicals These include urea, a hydrating and keratolytic agent; N, N- dimethyl- m toluamide; Calcium thioglycolate; Anticholinergic agents. Some implicit saturation enhancers have lately been described but the available data on their activeness are meager. These include eucalyptol, di- o- methyl- beta cyclodextrin and soyabean casein.

Other Excipients Adhesives:

The fastening of transdermal bias to the skin has so far been done by using a pressure sensitive glue. The pressure sensitive glue can be deposited on the face of the device or in the reverse of the device and extending peripherally. Both tenacious systems should fulfill the following criteria Should not irritate or acclimatize the skin or beget an imbalance in the normal skin foliage. Should cleave to the skin aggressively during the dosing interval without its position being disturbed by conditioning similar as bathing, exercise etc.

Table 3: Marketed products of Transdermal drug delivery system.

Product name	Drug	Manufacturer	Indication
Androderm	Testosterone	TheraTech/GlaxoSmithKline	Hypogonadism (males)
Nitro-dur	Nitroglycerin	Key Pharmaceuticals	Angina pectoris
Nitrodisc	Nitroglycerin	Roberts Pharmaceuticals	Angina pectoris
Minitran	Nitroglycerin	3M Pharmaceuticals	Angina pectoris
Deponit	Nitroglycerin	Schwarz-Pharma	Angina pectoris
Climaderm	Estradiol	Ethical Holdings/Wyeth-Ayerest	Postmenstrualsyndrome
Climara	Estradiol	3M Pharmaceuticals/Berlex Labs	Postmenstrual syndrome
Estraderm	Estradiol	Alza/Norvatis	Postmenstrual syndrome
Fematrix	Estrogen	Ethical Holdings/Solvay Healthcare	Postmenstrual syndrome
FemPatch	Estradiol	Parke-Davis	Postmenstrual syndrome
Alora	Estradiol	TheraTech/Proctol and Gamble	Postmenstrual syndrome
Prostep	Nicotine	Elan Corp./Lederle Labs	Smoking cessation
Nicoderm	Nicotine	Alza/GlaxoSmithKline	Smoking cessation
Habitraol	Nicotine	Novartis	Smoking cessation
Nuvelle TS	Estrogen/Progesterone	Ethical Holdings/Schering	Hormone replacement therapy
CombiPatch	Estradiol/Norethindrone	Noven ,Inc./Aventis	Hormone replacement therapy
Ortho-Evra	Norelgestromin/estradiol	Ortho-McNeil Pharmaceuticals	Birth control
Duragesic	Fentanyl	Alza/Janssen Pharmaceutic	a Moderate/severe pain
Catapres-TTS	Clonidine	Alza/Boehinger Ingelheim	Hypertension

Future of Transdermal Drug Delivery System

unborn new expression approaches and technologies include liposomes, noisome and micro conflation. Aim of this strategy is to ameliorate delivery of medicines that have low essential solubility in utmost classical expression excipients. A wide range of implicit medicines for delivery like steroids, antifungal, antibacterial, interferon, methotrexate, original anesthetics are formulated. The request for transdermal bias has been estimated to increase in future and has lately endured periodic growth of at rate of 25. This figure will rise in future as new bias crop and the list of retailed transdermal medicines increases. Transdermal delivery of anesthetics is likely to continue to increase in fashion ability as there are farther advancements in design. Research is being performed to increase safety and effective. To ameliorate practical matters similar as the experience for the wear and tear of the patch, and also to give more precise medicine delivery associated with increased duration of action. Other implicit advancements include bettered transdermal technology that utilizes mechanical energy to increase medicine flux across the skin either by altering the skin hedge or adding the energy of the medicine motes. After the successful design of patches using iontophoresis, colorful modes of ‘active' transdermal technologies are being delved for different medicines. These include electroporation (short electrical beats of high voltage to produce flash waterless pores in the skin), sonophoresis (uses low frequency ultrasonic energy to disrupt the stratum corneum), and thermal energy (uses heat to make the skin more passable and to increase the energy of medicine motes). glamorous energy, magnetophoretic, has been delved as a means to

increase medicine flux across the skin. The transdermal patch may be an underutilized tool for operation of acute and habitual pain. With bettered delivery and a wider range of anesthetics, we anticipate the fashion ability and connection of this modality to deliver medicines to increase. In current script, transdermal route of medicine delivery system in comparison with oral treatment as the most successful innovative exploration area in new medicine delivery system, with around 40 of the medicine delivery seeker products under clinical trials related to transdermal or dermal system. The transdermal medicine delivery systems (TDDS) have been designed as a volition, safest and easy route for systemic medicine delivery. The systemic medicine administration through skin holds several advantages similar as maintaining constant medicine position in blood tube, a smaller number of side goods, and enhancement of bioavailability by endurance of hepatic first pass metabolism and increase patient compliance with respect to medicine governance used for treatment. In recent times, skin is considered as a safest harborage for medicine administration, to give nonstop medicine release into systemic rotation.

Conclusion:

Transdermal drug delivery systems have been used as safe and effective drug delivery devices since 1981. A lot of progress has been done in the field of Transdermal Patches. Due to large advantages of the Transdermal Drug Delivery System, this system interests a lot of researchers. Many new researches are going on in the present day to incorporate newer drugs via this system. Transdermal dosage forms may provide clinicians an opportunity to o er more therapeutic options to their patients to optimize their care. The foregoing shows that TDDS have great potentials, being able to use for both hydrophobic and hydrophilic active substance into promising deliverable drugs. To optimize this drug delivery system, greater understanding of the different mechanisms of biological interactions, and polymer are required. TDDS a realistic practical application as the next generation of drug delivery systems

. References

: 1. Vyas S.P. and R.K Khar, Controlled drug delivery concepts and advances. Vallabh Prakash an, 1, 2002 411-447.

2. Prausnitz, M. R., Mitragotri, S. & Langer, R. Current Status and Future Potential of Transdermal Drug Delivery. Nature Reviews 3(2), 2004, 115-124.

3. Loyd V. Allen Jr, Nicholas G. Popovich, Howard C. Ansel. Pharmaceutical dosage forms and 8th Edition., Wolter Kluwer Publishers, New Delhi, 2005 pp. 298-299

. 4. Yie W,Chien, Novel Drug Delivery Systems, 2nd ed, M. Dekker, 2005, 50, 301-380

5. Eseldin Keleb, Rakesh Kumar Sharma, Transdermal Drug Delivery System-Design and Evaluation, International Journal of Advances in Pharmaceutical Sciences, 2010, 1(3), 201-211

6. Chien YW, Novel drug delivery systems, drugs and the pharmaceutical sciences, Vol.50, Marcel Dekker, New York, NY, 1992, 797

. 7. Gros L., Clark W.E., "The structure of skin" in "The tissue of the body" Le Gros Clark W. E. (editors) edition VI, ELBS and Oxford University Press, London, 1980, 29-313.

8. Chien Y.W.," Systemic delivery of pharmacologically active molecules across skin" in "Targeted drug delivery" Radolph L., Juliano (Editor) Springer- Verlag, Berlin, 1991, 182-230.

9. The skin & the sensory organs, chapter-12, "Cunningham's textbook of anatomy", Romans G.J., (Editor), Edition XXII, Oxford University press, NY, US, 1981, 829-34.

10. Lee WR, Shen SC, Lai HH, Hu CH, Fang JY. Transdermal drug delivery enhanced and controlled by erbium laser. J controlled release. 2001; 75:155-166

. 11. Willams AC, Barry B W. Penetration Enhancers. Adv Drug Del Rev. 2004; 56:603-618.

12.Jain Uncontrolled and Novel drug delivery, published by CBS Publishers & distributors, New Delhi-110002, 1st End, 1997, 100-129.